GL Pharm Tech

GL Pharm Tech Equity

The The Equity of GL Pharm Tech (204840.KQ) as of Oct 23, 2026 is 19.92 B KRW. In the previous year, The Equity was 19.67 B KRW — a change of 1.28% (higher).

Equity

19.92 BKRW

YoY

1.28%

Last updated:

In 2025, GL Pharm Tech's equity was 19.92 B KRW, a 1.28% increase from the 19.67 B KRW equity in the previous year.

The GL Pharm Tech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
7.82 B KRW
Jan 1, 2019
2.36 B KRW
Jan 1, 2020
14.31 B KRW
Jan 1, 2021
16.85 B KRW
Jan 1, 2022
16.09 B KRW
Jan 1, 2023
12.28 B KRW
Jan 1, 2024
19.67 B KRW
Jan 1, 2025
19.92 B KRW
The GL Pharm Tech Equity history
YEAREquityYoY
19.92 BKRW+1.28%
19.67 BKRW+60.13%
12.28 BKRW-23.67%
16.09 BKRW-4.50%
16.85 BKRW+17.71%
14.31 BKRW+506.12%
2.36 BKRW-69.79%
7.82 BKRW+31.70%
5.94 BKRW-30.73%
8.57 BKRW+217.81%
2.70 BKRW-68.05%
8.44 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GL Pharm Tech Stock analysis

What does GL Pharm Tech do? GL Pharm Tech Corp, based in Seongnam, South Korea, operates in the Health Care sector, specializing in pharmaceutical research and development services as well as the manufacturing and sale of pharmaceutical products. Listed on the stock market on 20 November 2014, the company focuses on developing and supplying pharmaceutical solutions within the Korean market. GL Pharm Tech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing GL Pharm Tech's Equity

GL Pharm Tech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding GL Pharm Tech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating GL Pharm Tech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

GL Pharm Tech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in GL Pharm Tech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about GL Pharm Tech stock

The Equity of GL Pharm Tech is 19.92 B KRW in 2025.

The Equity of GL Pharm Tech changed from 19.67 B KRW to 19.92 B KRW, representing a 1.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity GL Pharm Tech since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's GL Pharm Tech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GL Pharm Tech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GL Pharm Tech